Literature DB >> 30287443

Lesson of the month 1: Sodium valproate-induced encephalopathy.

Lara Camilleri1.   

Abstract

A 69-year-old man developed reduced consciousness of sudden onset. Examination and parameters were normal, except for a Glasgow Coma Scale (GCS) score of six. Brain imaging and blood tests were also normal, except for high plasma ammonia. His past medical history included epilepsy, hypertension and colitis. He was taking multiple antiepileptic medications, including sodium valproate, with no recent dose alterations. Medical intervention led to the sodium valproate being stopped and naloxone being administered. The patient's level of responsiveness and ammonia levels gradually improved. The patient was also being treated with ciprofloxacin for a urinary tract infection and a newly developed syndrome of inappropriate antidiuretic hormone secretion treated with demeclocycline. There is an association between long-term sodium valproate use and low carnitine levels, especially in the setting of polypharmacy. This in turn precipitates hyperammonaemia and encephalopathy. This case highlights the importance of an adequate drug history and the awareness of serious but uncommon adverse effects. © Royal College of Physicians 2018. All rights reserved.

Entities:  

Keywords:  Sodium valproate; encephalopathy; hyperammonaemia; naloxone

Mesh:

Substances:

Year:  2018        PMID: 30287443      PMCID: PMC6334110          DOI: 10.7861/clinmedicine.18-5-430

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  10 in total

1.  Valproate-induced hyperammonemic encephalopathy, rapidly improved by i.v. carnitine and glucose/thiamine.

Authors:  Thomas Bøhmer; Anne Bøen; Siv Cathrine Høymork
Journal:  Scand J Gastroenterol       Date:  2010-06       Impact factor: 2.423

Review 2.  Hyperammonemia due to valproic acid in the psychiatric setting.

Authors:  Russell B Carr; Kerrie Shrewsbury
Journal:  Am J Psychiatry       Date:  2007-07       Impact factor: 18.112

3.  Central nervous system manifestations of a valproic acid overdose responsive to naloxone.

Authors:  G Alberto; T Erickson; R Popiel; M Narayanan; D Hryhorczuk
Journal:  Ann Emerg Med       Date:  1989-08       Impact factor: 5.721

4.  Chronic valproic acid intoxication: reversal by naloxone.

Authors:  H K R Thanacoody
Journal:  Emerg Med J       Date:  2007-09       Impact factor: 2.740

5.  Valproic acid pathway: pharmacokinetics and pharmacodynamics.

Authors:  Yogita Ghodke-Puranik; Caroline F Thorn; Jatinder K Lamba; J Steven Leeder; Wen Song; Angela K Birnbaum; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2013-04       Impact factor: 2.089

6.  Hyperammonemia and coma developed by a woman treated with valproic acid for affective disorder.

Authors:  E Eze; M Workman; B Donley
Journal:  Psychiatr Serv       Date:  1998-10       Impact factor: 3.084

7.  Naloxone as a GABA antagonist: evidence from iontophoretic, receptor binding and convulsant studies.

Authors:  R Dingledine; L L Iversen; E Breuker
Journal:  Eur J Pharmacol       Date:  1978-01-01       Impact factor: 4.432

Review 8.  Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?

Authors:  Philippe E R Lheureux; Andrea Penaloza; Soheil Zahir; Mireille Gris
Journal:  Crit Care       Date:  2005-06-10       Impact factor: 9.097

9.  Hyperammonemia associated with valproic acid concentrations.

Authors:  Marta Vázquez; Pietro Fagiolino; Cecilia Maldonado; Ismael Olmos; Manuel Ibarra; Silvana Alvariza; Natalia Guevara; Laura Magallanes; Ivette Olano
Journal:  Biomed Res Int       Date:  2014-04-29       Impact factor: 3.411

10.  Valproic Acid-induced hyperammonemia in the elderly: a review of the literature.

Authors:  Vikrant Mittal; Sunanda Muralee; Rajesh R Tampi
Journal:  Case Rep Med       Date:  2009-08-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.